Vadimezan

Drug Profile

Vadimezan

Alternative Names: 5,6-MeXAA; AS 1404; ASA 404; Dimethylxanthenone acetic acid; DMXAA; NSC-640488; R1564

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Auckland Cancer Society Research Centre
  • Developer Antisoma; Auckland Cancer Society Research Centre; Novartis
  • Class Antineoplastics; Small molecules; Xanthones
  • Mechanism of Action Vascular disrupting agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Non-small cell lung cancer; Ovarian cancer; Prostate cancer; Urogenital cancer

Most Recent Events

  • 11 Nov 2010 Discontinued - Phase-II for Prostate cancer in Australia (IV)
  • 11 Nov 2010 Discontinued - Phase-II for Prostate cancer in USA (IV)
  • 11 Nov 2010 Discontinued - Phase-II for Urogenital cancer in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top